[SCHEDULE 13G] Silo Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

SILO issuer Silo Pharma, Inc. has a Schedule 13G filed by SEG Opportunity Fund, LLC reporting beneficial ownership of 952,381 shares of common stock, representing 7.1% of the class based on 13,318,273 shares outstanding after a Registered Direct Offering closed October 1, 2025. The filing shows shared voting and shared dispositive power over those shares and no sole voting or dispositive power.

The filer certifies the shares were not acquired to change or influence control of the issuer. The filing is dated 10/03/2025 and lists SEG Opportunity Fund as a New York LLC with its address in Roslyn, NY. This is a passive ownership disclosure under Schedule 13G.

Positive

• Beneficial ownership disclosed at 952,381 shares (7.1%), meeting regulatory transparency
• Certification included stating shares were not acquired to influence control, consistent with passive Schedule 13G status

Negative

• None.

Insights

Institutional Ownership Analyst

SEG Opportunity Fund reports a 7.1% passive stake in Silo Pharma.

The filing discloses 952,381 shares, equal to 7.1% of the outstanding common stock after the October 1, 2025 offering. This surpasses the 5% reporting threshold and must be disclosed publicly.

The statement indicates shared voting and shared dispositive power only and includes a certification that the stake was not acquired to influence control, consistent with a passive investor filing under Schedule 13G.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Silo Pharma, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

82711P201

(CUSIP Number)

09/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 82711P201

1

Names of Reporting Persons

SEG Opportunity Fund, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 952,381.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 952,381.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

952,381.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: (1) Based on 13,318,273 shares of Common Stock of the Issuer outstanding after the closing of the Registered Direct Offering of shares of Common Stock and Warrants of the Issuer on October 1, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silo Pharma, Inc.
(b)	Address of issuer's principal executive offices: 677 N. Washington Boulevard Sarasota, FL 34236
Item 2.
(a)	Name of person filing: This statement is filed by SEG Opportunity Fund, LLC, a New York limited liability company.
(b)	Address or principal business office or, if none, residence: The address of SEG Opportunity Fund, LLC is 135 Sycamore Drive Roslyn, NY 11576.
(c)	Citizenship: SEG Opportunity Fund, LLC is a New York limited liability company.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 82711P201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover pages(s) hereto.
(b)	Percent of class: See Item 11 on the cover page(s) hereto.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SEG Opportunity Fund, LLC

Signature:	/s/ Joseph Reda
Name/Title:	Joseph Reda/Manager
Date:	10/03/2025

FAQ

What stake in Silo Pharma (SILO) did SEG Opportunity Fund report?

SEG Opportunity Fund reported beneficial ownership of 952,381 shares, representing 7.1% of Silo Pharma's outstanding common stock.

Does SEG Opportunity Fund have sole voting control of the shares?

No. The filing reports 0 shares with sole voting power and 952,381 shares with shared voting power.

When is the ownership percentage calculated from?

The 7.1% figure is based on 13,318,273 shares outstanding after the Registered Direct Offering that closed on October 1, 2025.

Was the position filed as an attempt to influence control of Silo Pharma?

The filer certified the securities were not acquired to change or influence control and the filing is submitted as a Schedule 13G passive disclosure.

Who signed the Schedule 13G for SEG Opportunity Fund?

The filing was signed by Joseph Reda, Manager of SEG Opportunity Fund, LLC, on 10/03/2025.